Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 10, 2008

Avexa to Use Monogram’s Assays in HIV Drug R&D

  • Monogram Biosciences has become the exclusive provider of HIV resistance and tropism-testing technology to support Avexa's  drug discovery and development programs.

    Avexa plans to use Monogram's assays across its virology portfolio including the Phase III evaluation of its lead compound, apricitabine (ATC), a nucleoside reverse transcriptase inhibitor (NRTI) drug.

    Avexa will utilize Monogram's PhenoSense™ GT assay to select patients and optimize background therapy for trials involving approximately 2,000 patients and to monitor response to drug treatment during the studies.

    ATC is a new nucleoside analog that is intended for use in patients who have developed viral resistance to existing drugs. Avexa also has HIV drugs in early development in the CCR5- and integrase- inhibitor classes.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »